Research advances in peptide‒drug conjugates
Peptide‒drug conjugates (PDCs) are drug delivery systems consisting of a drug covalently coupled to a multifunctional peptide via a cleavable linker. As an emerging prodrug strategy, PDCs not only preserve the function and bioactivity of the peptides but also release the drugs responsively with the...
Gespeichert in:
Veröffentlicht in: | Acta pharmaceutica Sinica. B 2023-09, Vol.13 (9), p.3659-3677 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Peptide‒drug conjugates (PDCs) are drug delivery systems consisting of a drug covalently coupled to a multifunctional peptide via a cleavable linker. As an emerging prodrug strategy, PDCs not only preserve the function and bioactivity of the peptides but also release the drugs responsively with the cleavable property of the linkers. Given the ability to significantly improve the circulation stability and targeting of drugs in vivo and reduce the toxic side effects of drugs, PDCs have already been extensively applied in drug delivery. Herein, we review the types and mechanisms of peptides, linkers and drugs used to construct PDCs, and summarize the clinical applications and challenges of PDC drugs.
Peptide-drug conjugates (PDCs) enter the cell by direct penetration or mediated endocytosis of peptide, and then the linker is stimulated to cleave responsively, resulting in the release of the drug. [Display omitted] |
---|---|
ISSN: | 2211-3835 2211-3843 |
DOI: | 10.1016/j.apsb.2023.02.013 |